MoonLake Immunotherapeutics
MLTX
MLTX
83 hedge funds and large institutions have $2.86B invested in MoonLake Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
93% more funds holding
Funds holding: 43 → 83 (+40)
27.75% more ownership
Funds ownership: 100.69% → 128.44% (+28%)
Holders
83
Holding in Top 10
10
Calls
–
Puts
–
Top Buyers
| 1 | +$148M | |
| 2 | +$88M | |
| 3 | +$63.7M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$58.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$56.7M |
Top Sellers
| 1 | -$46M | |
| 2 | -$15.1M | |
| 3 | -$7.47M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.55M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.95M |